FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1552071134> ?p ?o ?g. }

• W1552071134 abstract "Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg). However, while ACE inhibitors have been shown to reduce mortality and morbidity in placebo-controlled trials, ARBs have not. Therefore, a comparison of the efficacies of these two drug classes in primary hypertension for preventing total mortality and cardiovascular events is important.To compare the effects of ACE inhibitors and ARBs on total mortality and cardiovascular events, and their rates of withdrawals due to adverse effects (WDAEs), in people with primary hypertension.We searched the Cochrane Hypertension Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the World Health Organization (WHO) International Clinical Trials Registry Platform, and the ISI Web of Science up to July 2014. We contacted study authors for missing and unpublished information, and also searched the reference lists of relevant reviews for eligible studies.We included randomized controlled trials enrolling people with uncontrolled or controlled primary hypertension with or without other risk factors. Included trials must have compared an ACE inhibitor and an ARB in a head-to-head manner, and lasted for a duration of at least one year. If background blood pressure lowering agents were continued or added during the study, the protocol to do so must have been the same in both study arms.We used standard methodological procedures expected by The Cochrane Collaboration.Nine studies with 11,007 participants were included. Of the included studies, five reported data on total mortality, three reported data on total cardiovascular events, and four reported data on cardiovascular mortality. No study separately reported cardiovascular morbidity. In contrast, eight studies contributed data on WDAE. Included studies were of good to moderate quality. There was no evidence of a difference between ACE inhibitors and ARBs for total mortality (risk ratio (RR) 0.98; 95% confidence interval (CI) 0.88 to 1.10), total cardiovascular events (RR 1.07; 95% CI 0.96 to 1.19), or cardiovascular mortality (RR 0.98; 95% CI 0.85 to 1.13). Conversely, a high level of evidence indicated a slightly lower incidence of WDAE for ARBs as compared with ACE inhibitors (RR 0.83; 95% CI 0.74 to 0.93; absolute risk reduction (ARR) 1.8%, number needed to treat for an additional beneficial outcome (NNTB) 55 over 4.1 years), mainly attributable to a higher incidence of dry cough with ACE inhibitors. The quality of the evidence for mortality and cardiovascular outcomes was limited by possible publication bias, in that several studies were initially eligible for inclusion in this review, but had no extractable data available for the hypertension subgroup. To this end, the evidence for total mortality was judged to be moderate, while the evidence for total cardiovascular events was judged to be low by the GRADE approach.Our analyses found no evidence of a difference in total mortality or cardiovascular outcomes for ARBs as compared with ACE inhibitors, while ARBs caused slightly fewer WDAEs than ACE inhibitors. Although ACE inhibitors have shown efficacy in these outcomes over placebo, our results cannot be used to extrapolate the same conclusion for ARBs directly, which have not been studied in placebo-controlled trials for hypertension. Thus, the substitution of an ARB for an ACE inhibitor, while supported by evidence on grounds of tolerability, must be made in consideration of the weaker evidence for the efficacy of ARBs regarding mortality and morbidity outcomes compared with ACE inhibitors. Additionally, our data mostly derives from participants with existing clinical sequelae of hypertension, and it would be useful to have data from asymptomatic people to increase the generalizability of this review. Unpublished subgroup data of hypertensive participants in existing trials comparing ACE inhibitors and ARBs needs to be made available for this purpose." @default.
• W1552071134 created "2016-06-24" @default.
• W1552071134 creator A5018015471 @default.
• W1552071134 creator A5051166300 @default.
• W1552071134 creator A5076883749 @default.
• W1552071134 date "2014-08-22" @default.
• W1552071134 modified "2023-10-18" @default.
• W1552071134 title "Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension" @default.
• W1552071134 cites W1485832218 @default.
• W1552071134 cites W1508421392 @default.
• W1552071134 cites W1901829674 @default.
• W1552071134 cites W1928353480 @default.
• W1552071134 cites W1969927198 @default.
• W1552071134 cites W1980236207 @default.
• W1552071134 cites W1984061204 @default.
• W1552071134 cites W1992044918 @default.
• W1552071134 cites W2001062021 @default.
• W1552071134 cites W2011581788 @default.
• W1552071134 cites W2012608113 @default.
• W1552071134 cites W2021011733 @default.
• W1552071134 cites W2024635091 @default.
• W1552071134 cites W2028302444 @default.
• W1552071134 cites W2035936679 @default.
• W1552071134 cites W2037877892 @default.
• W1552071134 cites W2043214899 @default.
• W1552071134 cites W2052769450 @default.
• W1552071134 cites W2057894304 @default.
• W1552071134 cites W2060507545 @default.
• W1552071134 cites W2077080091 @default.
• W1552071134 cites W2077470069 @default.
• W1552071134 cites W2100082183 @default.
• W1552071134 cites W2108620264 @default.
• W1552071134 cites W2115595776 @default.
• W1552071134 cites W2136651672 @default.
• W1552071134 cites W2143144750 @default.
• W1552071134 cites W2145555664 @default.
• W1552071134 cites W2152798629 @default.
• W1552071134 cites W2168907840 @default.
• W1552071134 cites W2170940856 @default.
• W1552071134 cites W2196103352 @default.
• W1552071134 cites W2396772514 @default.
• W1552071134 cites W4210957054 @default.
• W1552071134 cites W2085049923 @default.
• W1552071134 doi "https://doi.org/10.1002/14651858.cd009096.pub2" @default.
• W1552071134 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6486121" @default.
• W1552071134 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25148386" @default.
• W1552071134 hasPublicationYear "2014" @default.
• W1552071134 type Work @default.
• W1552071134 sameAs 1552071134 @default.
• W1552071134 citedByCount "90" @default.
• W1552071134 countsByYear W15520711342014 @default.
• W1552071134 countsByYear W15520711342015 @default.
• W1552071134 countsByYear W15520711342016 @default.
• W1552071134 countsByYear W15520711342017 @default.
• W1552071134 countsByYear W15520711342018 @default.
• W1552071134 countsByYear W15520711342019 @default.
• W1552071134 countsByYear W15520711342020 @default.
• W1552071134 countsByYear W15520711342021 @default.
• W1552071134 countsByYear W15520711342022 @default.
• W1552071134 countsByYear W15520711342023 @default.
• W1552071134 crossrefType "journal-article" @default.
• W1552071134 hasAuthorship W1552071134A5018015471 @default.
• W1552071134 hasAuthorship W1552071134A5051166300 @default.
• W1552071134 hasAuthorship W1552071134A5076883749 @default.
• W1552071134 hasBestOaLocation W15520711342 @default.
• W1552071134 hasConcept C126322002 @default.
• W1552071134 hasConcept C142724271 @default.
• W1552071134 hasConcept C168563851 @default.
• W1552071134 hasConcept C197934379 @default.
• W1552071134 hasConcept C204787440 @default.
• W1552071134 hasConcept C27016395 @default.
• W1552071134 hasConcept C27081682 @default.
• W1552071134 hasConcept C535046627 @default.
• W1552071134 hasConcept C71924100 @default.
• W1552071134 hasConcept C84393581 @default.
• W1552071134 hasConcept C95190672 @default.
• W1552071134 hasConceptScore W1552071134C126322002 @default.
• W1552071134 hasConceptScore W1552071134C142724271 @default.
• W1552071134 hasConceptScore W1552071134C168563851 @default.
• W1552071134 hasConceptScore W1552071134C197934379 @default.
• W1552071134 hasConceptScore W1552071134C204787440 @default.
• W1552071134 hasConceptScore W1552071134C27016395 @default.
• W1552071134 hasConceptScore W1552071134C27081682 @default.
• W1552071134 hasConceptScore W1552071134C535046627 @default.
• W1552071134 hasConceptScore W1552071134C71924100 @default.
• W1552071134 hasConceptScore W1552071134C84393581 @default.
• W1552071134 hasConceptScore W1552071134C95190672 @default.
• W1552071134 hasLocation W15520711341 @default.
• W1552071134 hasLocation W15520711342 @default.
• W1552071134 hasLocation W15520711343 @default.
• W1552071134 hasLocation W15520711344 @default.
• W1552071134 hasOpenAccess W1552071134 @default.
• W1552071134 hasPrimaryLocation W15520711341 @default.
• W1552071134 hasRelatedWork W1964352248 @default.
• W1552071134 hasRelatedWork W2043733257 @default.
• W1552071134 hasRelatedWork W2058308329 @default.
• W1552071134 hasRelatedWork W2085830368 @default.
• W1552071134 hasRelatedWork W2139520708 @default.
• W1552071134 hasRelatedWork W2154428559 @default.
• W1552071134 hasRelatedWork W2351076892 @default.

• next